Cirrhosis the end stage of chronic liver disease characterized
|
|
- Felicity Alexander
- 5 years ago
- Views:
Transcription
1 Suzanne E. Minor, MD, FAAFP; Irmanie Eliacin, MD; Sanaz Kashan, MD; Ebony B. Whisenant, MD Florida International University, Herbert Wertheim College of Medicine, Miami The authors reported no potential conflict of interest relevant to this article. Cirrhosis complications: Keeping them under control Ascites, variceal bleeding, hepatic encephalopathy, and hepatorenal syndrome are among the complications you are likely to encounter when caring for a patient with cirrhosis. This resource can help you refine your care. Practice recommendations Prescribe low-dose diuretics and recommend sodium restriction for patients with cirrhosis who have grade 2 (moderate) ascites. C Initiate treatment with beta-blockers to prevent variceal bleeding in all patients with medium or large varices, as well as in those with small varices who also have red wale signs and/or Child-Pugh Class B or C cirrhosis. A Consider evaluation for liver transplantation for a patient with cirrhosis who has experienced a major complication (eg, ascites, hepatic encephalopathy, or variceal hemorrhage) or one who has a model for end-stage liver disease (MELD) score 15. A Strength of recommendation (SOR) A Good-quality patient-oriented evidence B Inconsistent or limited-quality patient-oriented evidence C Consensus, usual practice, opinion, disease-oriented evidence, case series CASE u Joe M, age 59, seeks care at the local emergency department (ED) for shortness of breath. He also complains that his abdomen has been getting bigger and bigger. The ED physician recognizes that he is suffering from cirrhosis with secondary ascites and admits him. A paracentesis is performed and 7 L of fluid are removed. The patient is started on furosemide 40 mg/d and the health care team educates him about the relationship between his alcohol consumption and his enlarging abdomen. At discharge, he is told to follow up with his primary care physician. Two weeks later, the patient arrives at your clinic for followup. What is the next step in managing this patient? Cirrhosis the end stage of chronic liver disease characterized by inflammation and fibrosis is a relatively common and often fatal diagnosis. In the United States, an estimated 633,000 adults have cirrhosis, 1 and each year approximately 32,000 people die from the condition. 2 The most common causes of cirrhosis are heavy alcohol use, chronic hepatitis B or C infection, nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis. 3 Cirrhosis typically involves degeneration and necrosis of hepatocytes, which are replaced by fibrotic tissues and regenerative nodules, leading to loss of liver function. 4 Patients with cirrhosis can be treated as outpatients that is, until they decompensate. Obviously, treatment specific to the underlying causes of cirrhosis, such as interferon for a patient with hepatitis and abstinence for a patient with alcohol-related liver disease, should be the first concern. However, this article focuses on the family physician s role in identifying and treating several of the most common complications of cirrhosis, including ascites, variceal bleeding, hepatic encephalopathy, and hepatorenal syndrome. We will also cover which patients should be referred for evaluation for liver transplantation. (For a guide to 338 The Journal of Family Practice JUNE 2015 Vol 64, No 6
2 providing patient education for individuals with cirrhosis, see Dx cirrhosis: What to teach your patient 3,5-10 on page 341.) Sodium restriction, diuretics are first steps for ascites The goals of ascites treatment are to prevent or relieve dyspnea and abdominal pain and to prevent life-threatening complications, such as spontaneous bacterial peritonitis (SBP) and hepatorenal syndrome. 11 Patient education is key regarding weight gain; that s why it s important to instruct patients to contact you if they gain more than 2 lbs/d for 3 consecutive days or more than 10 lbs. 12 Approximately 10% of patients with ascites respond well to sodium restriction alone ( mg/d). 11 In addition to sodium restriction, patients with grade 2 ascites (moderate ascites with proportionate abdominal distension) should receive a low-dose diuretic, such as spironolactone (initial dose, mg/d; increase up to mg/d) 13 or amiloride (5-10 mg/d). 5 Painful gynecomastia and hyperkalemia are the most common adverse effects of spironolactone. 13 Amiloride has fewer adverse effects than spironolactone, but is less effective. 11 Low-dose furosemide (20-40 mg/d) may be added, although weight loss should be monitored to watch for excessive diuresis, which can lead to renal failure, hyponatremia, or encephalopathy. 5,13 Also monitor electrolytes to watch for hypokalemia or hyponatremia. 13 Recommended weight loss to prevent renal failure is 300 to 500 g/d ( lbs/d) for patients without peripheral edema, and 800 to 1000 g/d ( lbs/d) for patients with peripheral edema. 5,13 Patients with grade 3 (tense) or refractory ascites should have large-volume paracentesis (LVP) plus an albumin infusion. 5 LVP (removal of >5 L of fluid) is more effective, faster, and has less risk of adverse effects than increasing the dosage of the patient s diuretic. 5,13 LVP can be done in an outpatient setting and is considered safe even for patients with a prolonged prothrombin time. 13,14 Rare complications of LVP include significant bleeding at the puncture site, infection, and intestinal perforation. 5 Diuretics should be prescribed after LVP to prevent ascites recurrence. 5 Plasma expanders can prevent hepatorenal syndrome, ascites recurrence, and dilutional hyponatremia. 5,11 Albumin is the most efficacious of these agents; 5,14 it is administered intravenously at a dose of 8 to 10 g/l of fluid removed. 13,15 Take steps to prevent variceal bleeding Soon after a patient is diagnosed with cirrhosis, he or she should undergo esophagogastroduodenoscopy to screen for the presence and size of varices. 16 Although they can t prevent esophagogastric varices, nonselective beta-blockers (NSBBs) are the gold standard for preventing first variceal hemorrhage in patients with small varices with red wale signs on the varices and/or Child-Pugh Class B or C cirrhosis (TABLE 17 ), and in all patients with medium or large varices. 18 Propranolol is usually started at 20 mg BID, or nadolol is started at 20 to 40 mg/d. 16 The NSBB dose is adjusted to the maximum tolerated dose, which occurs when the patient's heart rate is reduced to 55 to 60 beats/min. NSBBs are associated with poor survival in patients with refractory ascites and thus are contraindicated in these patients. 19 NSBBs also should not be taken by patients with SBP because use of these medications is associated with worse outcomes compared to those not receiving NSBBs. 20 Endoscopic variceal ligation is an alternative to NSBBs for the primary prophylaxis of variceal hemorrhage in patients with medium to large varices. 18 In particular, ligation should be considered for patients with high-risk varices in whom beta-blockers are contraindicated or must be discontinued because of adverse effects. 21 z Avoid nitrates in patients with varices because these agents do not prevent first variceal hemorrhage and have been associated with higher mortality rates in patients older than There is no significant additional benefit or mortality reduction associated with adding a nitrate to an NSBB. 22 Transjugular intrahepatic portosystemic shunt (TIPS) or surgically created shunts are reserved for patients for whom medical therapy fails. 18 continued Approximately 10% of patients with ascites respond well to sodium restriction alone. Vol 64, No 6 JUNE 2015 The Journal of Family Practice 339
3 TABLE Child-Pugh scoring system for classifying cirrhosis* 17 Points are given, as noted below, for each of 5 categories. Class A is defined as a total score of 6; Class B, 7 to 9; and Class C, 10. Score Bilirubin <2 mg/dl 2-3 mg/dl >3 mg/dl PT (INR) <4 sec (<1.7) 4-6 sec ( ) (>2.3) Albumin >3.5 g/dl g/dl <2.8 g/dl Ascites None Mild Severe Encephalopathy None Mild Severe INR, international normalized ratio; PT, prothrombin time. Endoscopic variceal ligation is an alternative to nonselective beta-blockers for preventing variceal hemorrhage in patients with medium to large varices. Mental status changes suggest hepatic encephalopathy Hepatic encephalopathy is a reversible impairment of neuropsychiatric function that is associated with impaired hepatic function. Because a patient with encephalopathy presents with an altered mental status, he or she may need to be admitted to the hospital for evaluation, diagnosis, and treatment. The goals of hepatic encephalopathy treatment are to identify and correct precipitating causes and lower serum ammonia concentrations to improve mental status. 15 Nutritional support should be provided without protein restriction unless the patient is severely proteinintolerant. 23 The recommended initial therapy is lactulose 30 to 45 ml 2 to 4 times per day, to decrease absorption of ammonia in the gut. The dose should be titrated until patients have 2 to 3 soft stools daily. 24 For patients who can t tolerate lactulose or whose mental status doesn t improve within 48 hours, rifaximin 400 mg orally 3 times daily or 550 mg 2 times daily is recommended. 25 Neomycin 500 mg orally 3 times a day or 1 g twice daily is a second-line agent reserved for patients who are unable to take rifaximin; however, its efficacy is not well established, and neomycin has been associated with ototoxicity and nephrotoxicity. 24 Watch for signs of kidney failure Hepatorenal syndrome is renal failure induced by severe hepatic injury and characterized by azotemia and decreased renal blood flow and glomerular filtration rate. 15 It is a diagnosis of exclusion. Hepatorenal syndrome is typically caused by arterial vasodilation in the splanchnic circulation in patients with portal hypertension. 15,26,27 Type 1 hepatorenal syndrome is characterized by at least a 2-fold increase in serum creatinine to a level of >2.5 mg/dl over more than 2 weeks. Patients typically have urine output <400 to 500 ml/d. Type 2 hepatorenal syndrome is characterized by less severe renal impairment; it is associated with ascites that does not improve with diuretics. 28 Patients with hepatorenal syndrome should not use any nephrotoxic agents, such as nonsteroidal anti-inflammatory drugs. Inpatient treatment is usually required and may include norepinephrine with albumin, terlipressin with midodrine, or octreotide and albumin. Patients who fail to respond to medical therapy may benefit from TIPS as a bridge until they can undergo liver transplantation. 29 When to consider liver transplantation The appropriateness and timing of liver transplantation should be determined on a case-by-case basis. For some patients with cirrhosis, transplantation may be the definitive treatment. For example, in some patients with hepatocellular carcinoma (HCC), liver transplantation is an option because transplantation can cure the tumor and underlying 340 The Journal of Family Practice JUNE 2015 Vol 64, No 6
4 cirrhosis cirrhosis. However, while transplantation is a suitable option for early HCC in patients with cirrhosis, it has been shown to have limited efficacy in patients with advanced disease who are not selected using specific criteria. 30 Referral for evaluation for transplantation should be considered once a patient with cirrhosis experiences a major complication (eg, ascites, variceal hemorrhage, or hepatic encephalopathy). 31 Another criterion for timing and allocation of liver transplantation is based on the statistical model for end-stage liver disease (MELD), which is used to predict 3-month survival in patients with cirrhosis based on the relationships between serum bilirubin, serum creatinine, and international normalized ratio values. 15 Liver transplantation should be considered for patients with a MELD score ,31 Such patients should be promptly referred to a liver transplantation specialist to allow sufficient time for the appropriate psychosocial assessments and medical evaluations, and for patients and their families to receive appropriate education on things like the risks and benefits of transplantation. 15 CASE u After evaluating Mr. M, you prescribe spironolactone 100 mg/d and furosemide 40 mg twice a day to address ascites, and propranolol which you titrate to 80 mg twice a day to prevent variceal hemorrhage. Mr. M is maintained on these medications and returns with his daughter, as he has been doing every 2 to 3 months. He is excited that he breathes easily as long as he avoids salt and takes his medications. He continues to see his hepatologist regularly, and his last paracentesis was 4 months ago. He has not used any alcohol Dx cirrhosis: What to teach your patient Patients with cirrhosis should be educated about complications of their condition, including ascites, esophageal varices, hepatic encephalopathy, hepatorenal syndrome, spontaneous bacterial peritonitis, and hepatocellular carcinoma (HCC). 5 It s important to explain that they will need to be evaluated every 6 months with serology and ultrasound to assess disease changes. 6 Annual screening for HCC should be done with ultrasound or computed tomography scanning with or without alpha-fetoprotein. 6 Ensure that your patient knows that he needs to receive the recommended immunizations. The Centers for Disease Control and Prevention recommends that patients with cirrhosis should receive annual influenza, pneumococcal 23, and hepatitis A and B series vaccinations. 7 Advise patients with cirrhosis to be cautious when taking any medications. Patients with cirrhosis should avoid nonsteroidal anti-inflammatory drugs because these medications encourage sodium retention, which can exacerbate ascites. 6 Acetaminophen use is discouraged, but should not be harmful unless the patient takes >2 g/d. 8 Emphasize the importance of eating a healthy diet. Malnutrition is common in patients with cirrhosis 3 and correlates with more severe disease and poorer outcomes, including mortality. 9 Nutritional recommendations for patients with alcohol-related liver disease include thiamine 50 mg orally or intramuscularly, and riboflavin and pyridoxine in the recommended daily doses. 10 Advise patients to take other vitamins, as needed, to treat any deficiencies. 9 since he was taught about the relationship between alcohol and his breathing. JFP CORRESPONDENCE Suzanne Minor, MD, FAAFP, Assistant Professor of Family Medicine, Department of Humanities, Health, & Society, Florida International University, Herbert Wertheim College of Medicine, SW 8th Street, AHC II, 554A, Miami, FL 33199; seminor@fiu.edu References 1. Scaglion S, Kliethermes S, Cao G, et al. The epidemiology of cirrhosis in the United States: A population-based study. J Clin Gastroenterol October 8. [Epub ahead of print.] 2. Murphy SL, Xu JQ, Kochanek KD. Deaths: Final data for National Vital Statistics Reports. National Center for Health Statistics Web site. Available at: nvsr61/nvsr61_04.pdf. Accessed April 30, National Institute of Diabetes and Digestive and Kidney Diseases. Cirrhosis. National Institute of Diabetes and Digestive and Kidney Diseases Web site. Available at: health-information/health-topics/liver-disease/cirrhosis/pages/ facts.aspx. Accessed April 30, Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol. 2014;20: Ginès P, Cárdenas A, Arroyo V, et al. Management of cirrhosis and ascites. N Eng J Med. 2004;350: Grattagliano I, Ubaldi E, Bonfrate L, et al. Management of liver cirrhosis between primary care and specialists. World J Gastroenterol. 2011;17: Centers for Disease Control and Prevention recommended immunizations for adults: By age. Centers for Disease Control and Prevention Web site. Available from: vaccines/schedules/downloads/adult/adult-schedule-easyread.pdf. Accessed April 28, Bacon BR. Cirrhosis and its complications. In: Fauci AS, Braunwald E, Kasper DL, et al, eds. Harrison s Principles of Internal Medicine. 18th ed. New York, NY: McGraw-Hill; Available from: kid=1130§ionid= Accessed April 28, O Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. continued Vol 64, No 6 JUNE 2015 The Journal of Family Practice 341
5 Am J Gastroenterol. 2010;105: cirrhosis 10. National Institute on Alcohol Abuse and Alcoholism. Alcohol Alert. Alcoholic liver disease. U.S. Department of Health & Human Services National Institute on Alcohol Abuse and Alcoholism Web site. Available at: publications/aa64/aa64.htm. Accessed April 18, Kashani A, Landaverde C, Medici V, et al. Fluid retention in cirrhosis: pathophysiology and management. QJM. 2008;101: Chalasani NP, Vuppalanchi RK. Ascites: A common problem in people with cirrhosis. July American College of Gastroenterology Web site. Available at: Accessed April 28, Kuiper JJ, van Buuren HR, de Man RA. Ascites in cirrhosis: a review of management and complications. Neth J Med. 2007;65: Biecker E. Diagnosis and therapy of ascites in liver cirrhosis. World J Gastroentol. 2011;17: Heidelbaugh JJ, Sherbondy M. Cirrhosis and chronic liver failure: Part II. Complications and treatment. Am Fam Physician. 2006;74: Garcia-Tsao G, Lim JK; Members of Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol. 2009;104: Infante-Rivard C, Esnaola S, Villeneuve JP. Clinical and statistical validity of conventional prognostic factors in predicting shortterm survival among cirrhotics. Hepatology. 1987;7: Garcia-Tsao G, Sanyal AJ, Grace ND, et al; Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46: Serste T, Melot C, Francoz C, et al. Deleterious effects of betablockers on survival in patients with cirrhosis and refractory ascites. Hepatology. 2010;52: Mandorfer M, Bota S, Schwabl P, et al. Nonselective b blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2014;146: e Sarin SK, Lamba GS, Kumar M, et al. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med. 1999;340: Garcia-Pagan JC, Feu F, Bosch J, et al. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med. 1991;114: Amodio P, Bemeur C, Butterworth R, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology. 2013;58: Sharma P, Sharma BC. Disaccharides in the treatment of hepatic encephalopathy. Metab Brain Dis. 2013;28: Jiang Q, Jiang XH, Zheng MH, et al. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol. 2008;20: Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009;361: Iwakiri Y. The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension. J Clin Gastroenterol. 2007;41(Suppl 3): S288-S Epstein M, Berk DP, Hollenberg NK, et al. Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med. 1970;49: Singh V, Ghosh S, Singh B, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 2012;56: Chua TC, Saxena A, Chu F, et al. Hepatic resection for transplantable hepatocellular carcinoma for patients within Milan and UCSF criteria. Am J Clin Oncol. 2012;35: Martin P, DiMartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59: Visit Cast a wider net for intimate partner violence Tanya Zakrison, MD, MPH INSTANT poll Approximately what percentage of patient visits in your office are for dyspepsia? Online exclusives CASE REPORT Burning pain allodynia and hyperesthesia sensitivity at left T5 dermatome Dx? RESIDENTS' RAPID REVIEW A 5-question monthly quiz to help you prepare for the family medicine certification exam. This month: Immunization Photo rounds Friday Test your diagnostic skills at photo-rounds-friday.html PLUS Today s headlines in family medicine Get updates from us on Facebook Twitter google www. 342 The Journal of Family Practice JUNE 2015 Vol 64, No 6
Management of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University
Management of Cirrhotic Complications Uncontrolled Ascites Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University Topic Definition, pathogenesis Current therapeutic options Experimental treatments
More informationBeta-blockers in cirrhosis: Cons
Beta-blockers in cirrhosis: Cons Eric Trépo MD, PhD Dept. of Gastroenterology. Hepatopancreatology and Digestive Oncology. C.U.B. Hôpital Erasme. Université Libre de Bruxelles. Bruxelles. Belgium Laboratory
More informationEDUCATION PRACTICE. Management of Refractory Ascites. Clinical Scenario. The Problem
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1187 1191 EDUCATION PRACTICE Management of Refractory Ascites ANDRÉS CÁRDENAS and PERE GINÈS Liver Unit, Institute of Digestive Diseases, Hospital Clínic,
More informationManagement of Cirrhosis Related Complications
Management of Cirrhosis Related Complications Ke-Qin Hu, MD, FAASLD Professor of Clinical Medicine Director of Hepatology University of California, Irvine Disclosure I have no disclosure related to this
More informationCIRRHOSIS Definition
Cirrhosis Update Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology Weill Cornell Medical College CIRRHOSIS Definition Irreversible fibrous
More informationManagement of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy
Management of Ascites and Hepatorenal Syndrome Florence Wong University of Toronto June 4, 2016 6/16/2016 1 Disclosures Gore & Associates: Consultancy Sequana Medical: Research Funding Mallinckrodt Pharmaceutical:
More informationREVIEW. Ariel W. Aday, M.D.,* Nicole E. Rich, M.D.,* Arjmand R. Mufti, M.D., and Shannan R. Tujios, M.D.
REVIEW CON ( The Window Is Closed ): In Patients With Cirrhosis With Ascites, the Clinical Risks of Nonselective beta-blocker Outweigh the Benefits and Should NOT Be Prescribed Ariel W. Aday, M.D.,* Nicole
More informationNorepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome
Norepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome Disclosure I have no conflicts of interest to disclose Name: Margarita Taburyanskaya Title: PharmD, PGY1 Pharmacy Practice Resident
More informationEnd-Stage Liver Disease (ESLD): A Guide for HIV Physicians
Slide 1 of 32 End-Stage Liver Disease (ESLD): A Guide for HIV Physicians Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California
More informationACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis
ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis Guadalupe Garcia-Tsao, M.D., 1 Arun J. Sanyal, M.D., 2 Norman D. Grace,
More informationEsophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph
Esophageal Varices Beta-Blockers or Band Ligation Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation? Risk of esophageal variceal
More informationSteps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV
Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,
More informationAscites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology
Ascites Management Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Disclosure 1. The speaker Atif Zaman, MD MPH have no relevant
More informationESLD a Guide for HIV Physicians. Marion Peters University of California San Francisco June 2015
ESLD a Guide for HIV Physicians Marion Peters University of California San Francisco June 2015 Disclosures Honararia from Johnson and Johnson Roche Merck Gilead Spouse employee of Hoffman La Roche Natural
More informationCare of the Patient With Cirrhosis
REVIEW Care of the Patient With Cirrhosis Anitha Yadav, M.D., and Hugo E. Vargas, M.D. Caring for patients with cirrhosis involves multidisciplinary and timely management of several complications while
More informationCLINICAL How Should a Hospitalized Patient with Newly Diagnosed Cirrhosis Be Evaluated and Managed?
CLINICAL How Should a Hospitalized Patient with Newly Diagnosed Cirrhosis Be Evaluated and Managed? The Hospitalist. 2016 August;2016(8) Author(s): Raj Sehgal, MD; Joshua Hanson, MD, MPH; Division OF The
More informationBETA-BLOCKERS IN CIRRHOSIS.PRO.
BETA-BLOCKERS IN CIRRHOSIS.PRO. Angela Puente Sánchez. MD PhD Hepatology Unit. Gastroenterology department Marques de Valdecilla University Hospital. Santander INTRODUCTION. Natural history of cirrhosis
More informationInitial approach to ascites
Ascites: Filling and Draining the Water Balloon Common Pathogenesis in Refractory Ascites, Hyponatremia, and Cirrhosis intrahepatic resistance sinusoidal portal hypertension Splanchnic vasodilation (effective
More informationThe Management of Ascites & Hepatorenal Syndrome. Florence Wong University of Toronto. Falk Symposium March 14, 2008
The Management of Ascites & Hepatorenal Syndrome Florence Wong University of Toronto Falk Symposium March 14, 2008 Management of Ascites Sodium Restriction Mandatory at all stages of ascites in order to
More informationEvidence-Base Management of Esophageal and Gastric Varices
Evidence-Base Management of Esophageal and Gastric Varices Rino Alvani Gani Hepatobiliary Division Department of Internal Medicine Faculty of Medicine Universitas Indonesia Cipto Mangunkusumo National
More informationJOURNAL PRESENTATION. Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013
JOURNAL PRESENTATION Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013 THE COMBINATION OF OCTREOTIDE AND MIDODRINE IS NOT SUPERIOR TO ALBUMIN IN PREVENTING RECURRENCE OF ASCITES AFTER LARGE-VOLUME PARACENTESIS
More informationProgram Disclosure. This program is supported by an educational grant from Salix Pharmaceuticals.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship
More informationConflict of interest disclosures. Complications of end stage liver disease. None. The many complications of Cirrhosis. Portal Hypertension.
Complications of end stage liver disease Conflict of interest disclosures None Amir Qamar, MD Instructor of Medicine Brigham and Women s s Hospital Harvard Medical School Boston, MA 02115 The many complications
More informationHepatorenal Syndrome
Necker Seminars in Nephrology Institut Pasteur Paris, April 22, 2013 Hepatorenal Syndrome Dr. Richard Moreau 1 INSERM U773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, 2 Université Paris Diderot
More informationPrimary Prophylaxis against Variceal Hemorrhage Pharmacotherapy vs Endoscopic Band Ligation
Primary Prophylaxis against Variceal Hemorrhage Pharmacotherapy vs Endoscopic Band Ligation Siwaporn Chainuvati, MD Faculty of Medicine Siriraj Hospital Outline Natural history of esophageal varices Which
More informationChronic Hepatic Disease
Chronic Hepatic Disease 10 th Leading Cause of Death Liver Functions Energy Metabolism Protein Synthesis Solubilization, Transport, and Storage Protects and Clears drugs, damaged cells Causes of Liver
More informationMANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT
MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT Sherona Bau, ACNP The Pfleger Liver Institute 200 UCLA Medical Plaza, Suite 214 Los Angeles, CA 90095 September 30, 2017 I
More informationThe Yellow Patient. Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust
The Yellow Patient Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust there s a yellow patient in bed 40. It s one of yours. Liver Cirrhosis Why.When.What.etc.
More informationLIVER CIRRHOSIS. The liver extracts nutrients from the blood and processes them for later use.
LIVER CIRRHOSIS William Sanchez, M.D. & Jayant A. Talwalkar, M.D., M.P.H. Advanced Liver Disease Study Group Miles and Shirley Fiterman Center for Digestive Diseases Mayo College of Medicine Rochester,
More informationCauses of Liver Disease in US
Learning Objectives Updates in Outpatient Cirrhosis Management Jennifer Guy, MD MAS Director, Liver Cancer Program California Pacific Medical Center guyj@sutterhealth.org Review cirrhosis epidemiology,
More informationHepatorenal syndrome. Jan T. Kielstein Departent of Nephrology Medical School Hannover
Hepatorenal syndrome Jan T. Kielstein Departent of Nephrology Medical School Hannover Hepatorenal Syndrome 1) History of HRS 2) Pathophysiology of HRS 3) Definition of HRS 4) Clinical presentation of HRS
More informationCOMPLICATIONS OF CIRRHOSIS: ASCITES & HEPATIC ENCEPHALOPATHY
COMPLICATIONS OF CIRRHOSIS: ASCITES & HEPATIC ENCEPHALOPATHY DR. ESTER YAGUDAYEVA CLINICAL PHARMACIST HOSPICE PHARMACY SOLUTIONS OBJECTIVES Understand the prognosis of End Stage Liver Disease (ESLD) Identify
More informationProf. Mohammad Umar. MBBS, MCPS, FCPS, FACG (USA), FRCP (London), FRCP (Glasgow), FAGA
Prof. Mohammad Umar MBBS, MCPS, FCPS, FACG (USA), FRCP (London), FRCP (Glasgow), FAGA Chairman and Head Department of Medicine Rawalpindi Medical College, Rawalpindi. Consultant Gastroenterologist / Hepatologist
More informationManaging Cirrhosis. Cirrhosis of the liver is a progressive, fibrosing. Ascites. By Cameron Ghent, MD, FRCPC. Complications of Cirrhosis
Focus on CME at the University of Western Ontario Managing Cirrhosis By Cameron Ghent, MD, FRCPC Cirrhosis of the liver is a progressive, fibrosing process resulting in nodule formation and microvascular
More informationTreating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC
Treating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC mino.mitri@ubc.ca No Conflict of Interest 157 patients 157 patients 6 transplanted Criteria Liver
More informationAlpha-1 Antitrypsin Deficiency: Liver Disease
Alpha-1 Antitrypsin Deficiency: Liver Disease Who is at risk to develop Alpha-1 liver disease? Alpha-1 liver disease may affect children and adults who have abnormal Alpha-1 antitrypsin genes. Keys to
More informationDISEASE LEVEL MEDICAL EVIDENCE PROTOCOL
DISEASE LEVEL MEDICAL EVIDENCE PROTOCOL 1. This Protocol sets out the medical evidence that must be delivered to the Administrator for proof of Disease Level. It is subject to such further and other Protocols
More informationThe Continuum of Care for Advanced Liver Disease: Partnering with the Liver Specialist. K V Speeg, MD, PhD UT Health San Antonio
The Continuum of Care for Advanced Liver Disease: Partnering with the Liver Specialist K V Speeg, MD, PhD UT Health San Antonio Objectives Review staging of liver disease Review consequences of end-stage
More informationIntravenous Furosemide and Human Albumin for Treatment of Cirrhotic Ascites: Useful or Harmful?
Ibnosina J Med BS 83 ARTICLE Intravenous Furosemide and Human Albumin for Treatment of Cirrhotic Ascites: Useful or Harmful? Faisal O. Abubakor, Hind I. Fallatah, Hisham O. Akbar Department of Medicine,
More informationNONSELECTIVE BETA-BLOCKERS IN PATIENTS WITH CIRRHOSIS: THE THERAPEUTIC WINDOW
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2016 vol. 120, no. 1 INTERNAL MEDICINE UPDATES NONSELECTIVE BETA-BLOCKERS IN PATIENTS WITH CIRRHOSIS: THE THERAPEUTIC WINDOW Mihaela Dimache 1,2*, Irina Gîrleanu 1,2,
More informationCirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association
CIRRHOSIS AND PORTAL HYPERTENSION Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association WHAT IS CIRRHOSIS? What is Cirrhosis? DEFINITION OF CIRRHOSIS
More informationTerlipressin: An Asset for Hepatologists!
DIAGNOSTIC AND THERAPEUTIC ADVANCES IN HEPATOLOGY Terlipressin: An Asset for Hepatologists! S.K. Sarin and Praveen Sharma One Case Scenario A 48-year-old male with alcoholic cirrhosis who was abstinent
More informationComplications of Cirrhosis
Complications of Cirrhosis Causes of Cirrhosis Alcohol Chronic Viral Hepatitis (B/C) Haemochromatosis Autoimmune Hepatitis NAFLD/NASH Primary Biliary Cirrhosis Primary Sclerosing Cholangitis 1-AT deficiency
More informationControversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate
Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate Patrick Northup, MD, FAASLD, FACG Medical Director, Liver Transplantation University of Virginia
More informationOptimal management of ascites
Optimal management of ascites P. Angeli, Dept. of Medicine, Unit of Internal Medicine and epatology (), University of Padova (Italy) pangeli@unipd.it 10th Paris epatology Conference National Conference
More informationManagement of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL
Management of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL Terminology Acute decompensation of cirrhosis - stable patient with sudden deterioration Acute-on-chronic liver failure
More informationManagement of the Cirrhotic Patient in the ICU
Management of the Cirrhotic Patient in the ICU Peter E. Morris, MD Professor & Chief, Pulmonary, Critical Care and Sleep Medicine University of Kentucky Conflict of Interest Funding US National Institutes
More information4/3/2014. Elizabeth Thompson, PharmD April Understand the importance of the liver and basic physiology.
Liver Disease Elizabeth Thompson, PharmD thompse@sarmc.org April 2014 Objectives Understand the importance of the liver and basic physiology. Review hepatic disorders Recognize liver function scoring systems
More informationEtiology of liver cirrhosis
Liver cirrhosis 1 Liver cirrhosis Liver cirrhosis is the progressive replacement of normal hepatic cells by fibrous scar tissue, This scarring is accompanied by the loss of viable hepatocytes, which are
More informationDefinition: fibrosis and nodular regeneration resulting from hepatocellular injury
Cirrhosis Understanding the liver: Patterns of LFT Abnormalities - Hepatocellular/Transaminitis: o Ratio of AST: ALT >2:1 ETOH (keep in mind AST is also produced by red cells, heart muscle) o If Aminotransferases
More informationManagement of Chronic Liver Failure/Cirrhosis Complications in Hospitals. By: Dr. Kevin Dolehide
Management of Chronic Liver Failure/Cirrhosis Complications in Hospitals By: Dr. Kevin Dolehide Overview DX Cirrhosis and Prognosis Compensated Decompensated Complications Of Cirrhosis Management Of Complications
More informationHepatology on the AMU
Hepatology on the AMU RCP day, 8 th February 2018 Jo Leithead Consultant in Hepatology and Liver Transplantation Addenbrookes Hospital Cambridge Is liver disease relevant to me? Williams R, Lancet 2014
More informationIs pharmacological therapy the best choice for primary prevention of variceal hemmorhaging in patients with hepatic cirrhosis?
Controversies en Gastroenterology Is pharmacological therapy the best choice for primary prevention of variceal hemmorhaging in patients with hepatic cirrhosis? Rolando José Ortega Quiroz, MD, 1 Adalgiza
More informationCHAPTER 7. End Stage Liver Disease in the ICU: Walking a Tightrope. Lynn A. Kelso, MSN, APRN, FCCM, FAANP University of Kentucky College of Nursing
CHAPTER 7 End Stage Liver Disease in the ICU: Walking a Tightrope Lynn A. Kelso, MSN, APRN, FCCM, FAANP University of Kentucky College of Nursing Besey Oren, Assistant Professor Istanbul University Health
More informationSign up to receive ATOTW weekly -
HEPATORENAL SYNDROME ANAESTHESIA TUTORIAL OF THE WEEK 240 10 TH SEPTEMBER 2011 Gerry Lynch Rotherham General Hospital Correspondence to gerry.lynch@rothgen.nhs.uk QUESTIONS Before continuing, try to answer
More informationLearning Objectives. After attending this presentation, participants will be able to:
Learning Objectives After attending this presentation, participants will be able to: Describe HCV in 2015 Describe how to diagnose advanced liver disease and cirrhosis Identify the clinical presentation
More informationEvaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA
Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death
More informationJMSCR Vol 05 Issue 11 Page November 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i11.33 Prevalence of Hyponatremia among patients
More informationLiver failure &portal hypertension
Liver failure &portal hypertension Objectives: by the end of this lecture each student should be able to : Diagnose liver failure (acute or chronic) List the causes of acute liver failure Diagnose and
More informationPortal hypertension is the main complication of cirrhosis
GASTROENTEROLOGY 2001;120:726 748 Current Management of the Complications of Cirrhosis and Portal Hypertension: Variceal Hemorrhage, Ascites, and Spontaneous Bacterial Peritonitis GUADALUPE GARCIA TSAO
More informationAscites is the most frequent complication of cirrhosis,
Beneficial Effect of Midodrine in Hypotensive Cirrhotic Patients with Refractory Ascites G & H C l i n i c a l C a s e S t u d i e s Achuthan Sourianarayanane, MD, MRCP 1 David S. Barnes, MD 1,2 Arthur
More informationCarvedilol or Propranolol in the Management of Portal Hypertension?
Evidence Based Case Report Carvedilol or Propranolol in the Management of Portal Hypertension? Arranged by: dr. Saskia Aziza Nursyirwan RESIDENCY PROGRAM OF INTERNAL MEDICINE DEPARTMENT UNIVERSITY OF INDONESIA
More informationEDUCATION PRACTICE. Cirrhosis With Refractory Ascites: Serial Large Volume Paracentesis, TIPS, or Transplantation?
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:931 935 EDUCATION PRACTICE Cirrhosis With Refractory Ascites: Serial Large Volume Paracentesis, TIPS, or Transplantation? VANDANA KHUNGAR* and SAMMY SAAB*,
More informationRENAL DISEASE IN END STAGE LIVER DISEASE
RENAL DISEASE IN END STAGE LIVER DISEASE Mitchell L Shiffman, MD Director Health System Richmond and Newport News, VA Medical Group Good Help to Those in Need Mitchell L Shiffman, MD POTENTIAL CONFLICTS
More informationFaculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014
Cirrhosis Management for the Family Physician Mang Ma, MD, FRCP Professor University of Alberta Faculty: Mang Ma Faculty Disclosure Relationships with commercial interests: Advisory Board: Merck, Gilead
More informationfollowing the last documented transfusion; thereafter, evaluate the residual impairment(s).
Adult Listings 5.01 Category of Impairments, Digestive System 5.02 Gastrointestinal hemorrhaging from any cause, requiring blood transfusion (with or without hospitalization) of at least 2 units of blood
More informationMedicines for Chronic Liver Disease
UW MEDICINE PATIENT EDUCATION Medicines for Chronic Liver Disease Treating common conditions This handout gives basic information about how the liver works and what happens during liver failure. It describes
More informationCIRCULATORY AND RENAL FAILURE IN CIRRHOSIS
CIRCULATORY AND RENAL FAILURE IN CIRRHOSIS Pere Ginès, MD Liver Unit, Hospital Clínic Barcelona, Catalunya, Spain CIRCULATORY AND RENAL FAILURE IN CIRRHOSIS Hecker R and Sherlock S, The Lancet 1956 RENAL
More informationHepatorenal syndrome. Jan Jan T. T. Kielstein Departent of of Nephrology Medical School School Hannover
Hepatorenal syndrome Jan Jan T. T. Kielstein Departent of of Nephrology Medical School School Hannover Hepatorenal Syndrome 1) History of HRS 2) Pathophysiology of HRS 3) Definition of HRS 4) Clinical
More informationArticle. Management of Decompensate Cirrhotic Patients Awaiting Liver Transplantation and Early Post-transplant Care INTRODUCTION.
THAI J 124 GASTROENTEROL and Early Post-transplant InvitedCare Management of Decompensate Cirrhotic Patients Awaiting Liver Transplantation and Early Post-transplant Care Article Sobhonslidsuk A INTRODUCTION
More informationVARICEAL BLEEDING. Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta.
VARICEAL BLEEDING Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta Disclosures: None OUTLINE Pathophysiology of portal hypertension Splanchnic
More informationGI bleeding in chronic liver disease
GI bleeding in chronic liver disease Stuart McPherson Consultant Hepatologist Liver Unit, Freeman Hospital, Newcastle upon Tyne and Institute of Cellular Medicine, Newcastle University. Case 54 year old
More informationCIRRHOTIC MANAGEMENT
DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care
More informationCase Report Low-Dose Tolvaptan for the Treatment of Dilutional Hyponatremia in Cirrhosis: A Case Report and Literature Review
Case Reports in Hepatology, Article ID 795261, 4 pages http://dx.doi.org/10.1155/2014/795261 Case Report Low-Dose Tolvaptan for the Treatment of Dilutional Hyponatremia in Cirrhosis: A Case Report and
More informationAscites is the most common complication of cirrhosis and. Natural History of Patients Hospitalized for Management of Cirrhotic Ascites
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:1385 1394 Natural History of Patients Hospitalized for Management of Cirrhotic Ascites RAMON PLANAS,* SILVIA MONTOLIU,* BELEN BALLESTÉ, MONICA RIVERA, MIREIA
More informationDiagnostic Procedures. Measurement of Hepatic venous pressure in management of cirrhosis. Clinician s opinion
5 th AISF Post-Meeting Course Diagnostic and Therapeutic Invasive Procedures in Hepatology Rome, February 25 th Diagnostic Procedures Measurement of Hepatic venous pressure in management of cirrhosis Clinician
More informationLife After SVR for Cirrhotic HCV
Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data
More informationEASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis
EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis European Association for the Study of the Liver 1 Ascites is the
More informationComplication of Portal Hypertension: should the patients in the waiting list be treated differently?
Wilma Debernardi Venon Gastroepatologia, Az. Osp. San Giovanni Battista ditorino Complication of Portal Hypertension: should the patients in the waiting list be treated differently? Il sottoscritto dichiara
More informationDenver Shunts vs TIPS for Ascites
Denver Shunts vs TIPS for Ascites Hooman Yarmohammadi MD Assistant Professor of Radiology Interventional Radiology & Image Guided Therapies Memorial Sloan-Kettering Cancer Center, New York, USA Hooman
More informationFrom Sodium Retention to Therapy for Refractory Ascites The Role for New Drugs. Florence Wong University of Toronto. Falk Symposium October 14, 2007
From Sodium Retention to Therapy for Refractory Ascites The Role for New Drugs Florence Wong University of Toronto Falk Symposium October 14, 2007 Sodium Retention in Cirrhosis Occurs as a result of hemodynamic
More informationTreatment of Overt Hepatic Encephalopathy: Focus on Outpatient Management
Treatment of Overt Hepatic Encephalopathy: Focus on Outpatient Management Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation
More informationOriginal Article. Noradrenaline is as Effective as Terlipressin in Hepatorenal Syndrome Type 1: A Prospective, Randomized Trial
30 Journal of The Association of Physicians of India Vol. 64 September 2016 Original Article Noradrenaline is as Effective as Terlipressin in Hepatorenal Syndrome Type 1: A Prospective, Randomized Trial
More informationMANAGING END STAGE LIVER DISEASE IN RESOURCE LIMITED SETTINGS
MANAGING END STAGE LIVER DISEASE IN RESOURCE LIMITED SETTINGS Mark W. Sonderup Division of Hepatology and Liver Laboratory Department of Medicine University of Cape Town & Groote Schuur Hospital Cirrhosis..
More informationPALLIATIVE CARE IN END-STAGE LIVER DISEASE
PALLIATIVE CARE IN END-STAGE LIVER DISEASE Ken S. Ota, DO Family Medicine Banner Good Samaritan Medical Center Learning Objectives: Describe the common bio-psycho-social issues in end-stage liver disease
More informationContraindications. Indications. Complications. Currently TIPS is considered second or third line therapy for:
Contraindications Absolute Relative Primary prevention variceal bleeding HCC if centrally located Active congestive heart failure Obstruction all hepatic veins Thomas D. Boyer, M.D. University of Arizona
More informationCase Report: Acute-on-Chronic Liver Failure: Making the Diagnosis between Infection and Acute Alcoholic Hepatitis
Diagnostic Problems in Hepatology 181 Case Report: Acute-on-Chronic Liver Failure: Making the Diagnosis between Infection and Acute Alcoholic Hepatitis Carmen Sendra, MD 1 Javier Ampuero, MD, PhD 1,2 Álvaro
More informationElevated Creatinine in a Patient With Cirrhosis
REVIEW Elevated Creatinine in a Patient With Cirrhosis Heather L. Klavan, M.D., and Brett E. Fortune, M.D., M.S. Elevation in serum creatinine is a common laboratory finding for patients with cirrhosis
More informationLong term administration of human albumin improves survival in patients with cirrhosis and refractory ascites
Received: 3 May 2018 Revised: 2 August 2018 Accepted: 12 September 2018 DOI: 10.1111/liv.13968 CIRRHOSIS AND LIVER FAILURE Long term administration of human albumin improves survival in patients with cirrhosis
More informationth Annual AISF Meeting 44 th th th, 2011 Rome, February 23 rd -26
44 th 44 th Annual AISF Meeting Rome, February 23 rd -26 th th, 2011 Update on the Baveno Consensus Conference Roberto de Franchis Department of of Clinical Sciences, University of of Milan, Head, Gastroenterology
More informationLiver Transplantation Evaluation: Objectives
Liver Transplantation Evaluation: Essential Work-Up Curtis K. Argo, MD, MS VGS/ACG Regional Postgraduate Course Williamsburg, VA September 13, 2015 Objectives Discuss determining readiness for transplantation
More informationAssociation between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia
doi: 10.2169/internalmedicine.0629-17 Intern Med 57: 2451-2458, 2018 http://internmed.jp ORIGINAL ARTICLE Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients
More informationVariceal bleeding. Mainz,
Variceal bleeding Mainz, 21.09.2008 Risk of complications 5 years 10 years Ascites 10 % 25 % HCC 10 % 25 % Bleeding < 5 % 5-10 % Enceph. < 5 % < 5 % Typical situation : Mortality 10 % to 40 % Sequence
More informationHepatology for the Nonhepatologist
Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning
More informationDecompensated chronic liver disease
Decompensated chronic liver disease Definition of decompensated chronic liver disease Patients with chronic liver disease can present with acute decompensation due to various causes. The decompensation
More informationDISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea
DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,
More informationTherapy Insight: management of hepatorenal syndrome
Therapy Insight: management of hepatorenal syndrome Andrés Cárdenas and Pere Ginès* SUMMARY Hepatorenal syndrome (HRS), a feared complication of advanced cirrhosis, is characterized by functional renal
More informationThe Importance of Diagnosing Covert Hepatic Encephalopathy
The Importance of Diagnosing Covert Hepatic Encephalopathy Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council
More information